XML 22 R5.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]      
Revenue [1] $ 1,963,896 $ 1,352,013 $ 907,957
Expenses      
Cost of revenue [1] 1,503,426 1,035,429 657,551
Selling, general and administrative expenses [1] 358,110 269,269 219,499
Depreciation and amortization expenses 123,415 67,195 60,037
Loss on disposal of non-strategic assets 8,107 0 0
Right-of-use assets impairment 24,065 0 0
Change in fair value of contingent consideration 17,984 (23,522) 13,281
Total operating expenses 2,035,107 1,348,371 950,368
Operating income (loss) (71,211) 3,642 (42,411)
Interest income 5,256 1,369 407
Interest expense (54,205) (15,572) (25,425)
Gain from equity method investees 1,290 4,569 13,179
Gain on transfer of membership 0 0 45,938
Loss on extinguishment/repayment on long-term debt, net (21,010) (10,192) (21,343)
Change in tax receivables agreement liability (61,982) (45,950) 0
Other income (expense), net (543) 57 (146)
Loss before income taxes (202,405) (62,077) (29,801)
Provision for (benefit from) income taxes (89,365) (43,376) 483
Loss from continuing operations (113,040) (18,701) (30,284)
Loss from discontinued operations, net of tax [2] 0 (463) (7,317)
Loss before preferred dividends and accretion of Series A Preferred Stock (113,040) (19,164) (37,601)
Dividends and accretion of Series A Preferred Stock (29,220) 0 0
Net (loss) attributable to common shareholders of Evolent Health, Inc. - Basic (142,260) (19,164) (37,601)
Net (loss) attributable to common shareholders of Evolent Health, Inc., Inc. - Diluted $ (142,260) $ (19,164) $ (37,601)
Basic and diluted:      
Continuing operations, basic (in dollars per share) $ (1.28) $ (0.20) $ (0.35)
Continuing operations, diluted (in dollars per share) (1.28) (0.20) (0.35)
Discontinued operations basic (in dollars per share) 0 0 (0.09)
Discontinued operations diluted (in dollars per share) 0 0 (0.09)
Basic loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share) (1.28) (0.20) (0.44)
Diluted loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share) $ (1.28) $ (0.20) $ (0.44)
Weighted-average common shares outstanding      
Basic (in shares) 111,251 93,699 86,067
Diluted (in shares) 111,251 93,699 86,067
Comprehensive loss      
Net loss attributable to common shareholders of Evolent Health, Inc. $ (142,260) $ (19,164) $ (37,601)
Other comprehensive loss, net of taxes, related to:      
Foreign currency translation adjustment (79) (816) (84)
Total comprehensive loss attributable to common shareholders of Evolent Health, Inc. $ (142,339) $ (19,980) $ (37,685)
[1] See Note 20 for amounts attributable to unconsolidated related parties included in these line items.
[2] Includes $0.5 million and $6.8 million loss on disposal of discontinued operations for the years ended December 31, 2022 and 2021, respectively